CN103974700B - 贴附剂 - Google Patents
贴附剂 Download PDFInfo
- Publication number
- CN103974700B CN103974700B CN201280060286.1A CN201280060286A CN103974700B CN 103974700 B CN103974700 B CN 103974700B CN 201280060286 A CN201280060286 A CN 201280060286A CN 103974700 B CN103974700 B CN 103974700B
- Authority
- CN
- China
- Prior art keywords
- mentioned
- agent layer
- adhering agent
- adhesive preparation
- diclofenac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 117
- 239000000853 adhesive Substances 0.000 title claims abstract description 107
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 107
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 122
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 72
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims abstract description 58
- 229960001259 diclofenac Drugs 0.000 claims abstract description 57
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 40
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 40
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 38
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 45
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 42
- 235000010265 sodium sulphite Nutrition 0.000 claims description 20
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 15
- 125000006353 oxyethylene group Chemical group 0.000 claims description 13
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 7
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 7
- 239000010410 layer Substances 0.000 description 128
- 238000012360 testing method Methods 0.000 description 31
- 231100000245 skin permeability Toxicity 0.000 description 30
- -1 polyol fatty acid ester Chemical class 0.000 description 22
- 230000036407 pain Effects 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 15
- 229960001193 diclofenac sodium Drugs 0.000 description 15
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 15
- 239000000470 constituent Substances 0.000 description 14
- 229960004063 propylene glycol Drugs 0.000 description 14
- 235000013772 propylene glycol Nutrition 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- 239000004744 fabric Substances 0.000 description 8
- 229920003169 water-soluble polymer Polymers 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 6
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 6
- 235000010262 sodium metabisulphite Nutrition 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000003431 cross linking reagent Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 150000005846 sugar alcohols Polymers 0.000 description 5
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000004584 polyacrylic acid Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 229920006132 styrene block copolymer Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004902 Softening Agent Substances 0.000 description 3
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical class C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 3
- 229920006243 acrylic copolymer Polymers 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000013032 Hydrocarbon resin Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N alpha-methacrylic acid Natural products CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical class OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229920006270 hydrocarbon resin Polymers 0.000 description 2
- 239000011256 inorganic filler Substances 0.000 description 2
- 229910003475 inorganic filler Inorganic materials 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-O 1-(2-hydroxyethyl)pyrrolidinium Chemical compound OCC[NH+]1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-O 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LVOGXJMCDAOKSQ-UHFFFAOYSA-N 10-oxo-10-propan-2-yloxydecanoic acid Chemical compound CC(C)OC(=O)CCCCCCCCC(O)=O LVOGXJMCDAOKSQ-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Chemical class C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- ONKUXPIBXRRIDU-UHFFFAOYSA-N Diethyl decanedioate Chemical compound CCOC(=O)CCCCCCCCC(=O)OCC ONKUXPIBXRRIDU-UHFFFAOYSA-N 0.000 description 1
- ADFOLUXMYYCTRR-ZIAGYGMSSA-N Dihydroguaiaretic acid Natural products C1=C(O)C(OC)=CC(C[C@@H](C)[C@H](C)CC=2C=C(OC)C(O)=CC=2)=C1 ADFOLUXMYYCTRR-ZIAGYGMSSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Chemical class O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- HTAWSOSQCJAPJB-UHFFFAOYSA-H [Al+3].NCC(=O)[O-].O[Al+]O.NCC(=O)[O-].NCC(=O)[O-].NCC(=O)[O-] Chemical compound [Al+3].NCC(=O)[O-].O[Al+]O.NCC(=O)[O-].NCC(=O)[O-].NCC(=O)[O-] HTAWSOSQCJAPJB-UHFFFAOYSA-H 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 238000009954 braiding Methods 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 229940039116 combination diclofenac Drugs 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 229950008932 epolamine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229920003049 isoprene rubber Polymers 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- ADFOLUXMYYCTRR-OKILXGFUSA-N meso-dihydroguaiaretic acid Chemical compound C1=C(O)C(OC)=CC(C[C@H](C)[C@H](C)CC=2C=C(OC)C(O)=CC=2)=C1 ADFOLUXMYYCTRR-OKILXGFUSA-N 0.000 description 1
- XFEICBDAXKWVBZ-KGLIPLIRSA-N meso-dihydroguaiaretic acid Natural products COc1ccc(C[C@@H](C)[C@@H](C)Cc2ccc(O)c(OC)c2)cc1O XFEICBDAXKWVBZ-KGLIPLIRSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Chemical class OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940032912 zephiran Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明是一种贴附剂,其具备支持体层与粘着剂层,上述粘着剂层含有双氯芬酸或其可药用的盐、甘油、丁二醇及聚乙二醇单油酸酯,并且上述丁二醇与上述聚乙二醇单油酸酯的质量比(丁二醇的质量∶聚乙二醇单油酸酯的质量)为1∶1~4∶1。
Description
技术领域
本发明涉及贴附剂。
背景技术
双氯芬酸是非类固醇系的镇痛、消炎药,除日本药典外,收录于世界各国的药典中。作为含有作为双氯芬酸的盐的双氯芬酸钠的制剂,不仅提供有锭剂、胶囊剂等经口剂,而且近年来也提供有凝胶剂、软膏剂、贴附剂等外用剂,广泛地用于变形性关节病、肩周炎等局部疾病的治疗。
此外,在这种外用剂中,自先前以来一直尝试确保双氯芬酸的稳定释放,例如在日本特开昭63-091318号公报(专利文献1)中,记载有含有双氯芬酸钠与1,3-丁二醇的贴附剂。进而,在日本特开平6-56660号公报(专利文献2)中,记载有含有双氯芬酸钠、水、多元醇脂肪酸酯及作为溶解助剂的1,3-丁二醇的贴附剂。然而,在这些贴附剂中,有双氯芬酸的皮肤透过性尚不充分这样的问题。
此外,作为以提高双氯芬酸的皮肤透过性为目的的贴附剂,在日本特开平10-182450号公报(专利文献3)中,记载有含有双氯芬酸、丙二醇、甘油等醇及表面活性剂等羧酸酯的贴附剂,作为上述表面活性剂,例示有聚乙二醇脂肪酸酯等。进而,在日本特开2002-193793号公报(专利文献4)中,记载有含有双氯芬酸钠、甘油及二醇的贴附剂,作为上述二醇,此外例示有丙二醇、1,3-丁二醇等。
此外,在日本特开昭61-060608号公报(专利文献5)中,记载有通过在含有双氯芬酸钠与水的敷剂中含有丙二醇(propyleneglycol)或丁二醇(butyleneglycol)等亚烷基二醇与明胶等基剂,而提高双氯芬酸的皮肤透过性;在日本特开平3-109321号公报(专利文献6)中,记载有通过在凝胶制剂中含有双氯芬酸与HLB值为14.5以下的非离子表面活性剂,而提高双氯芬酸的皮肤透过性;使用丙二醇作为上述凝胶制剂的共溶剂。
然而,如果在如上的贴附剂中使用丙二醇,则有存在产生发红、红斑、发疹、瘙痒感、疼痛的皮肤症状、或在剥离时产生疼痛的情况等问题,对皮肤的附着性不充分这样的问题。此外,如果以减少对皮肤的刺激而使用甘油来代替上述丙二醇,则有双氯芬酸的皮肤透过性降低这样的问题。
现有技术文献
专利文献
专利文献1:日本特开昭63-091318号公报
专利文献2:日本特开平6-56660号公报
专利文献3:日本特开平10-182450号公报
专利文献4:日本特开2002-193793号公报
专利文献5:日本特开昭61-060608号公报
专利文献6:日本特开平3-109321号公报
发明内容
发明所要解决的问题
本发明是鉴于上述现有技术所具有的课题而完成的,其目的在于提供一种剥离时的疼痛减少,对皮肤的刺激少,双氯芬酸的皮肤透过性优异,并且附着性也优异的贴附剂。
解决问题的手段
本发明者等人为了达成上述目的,反复进行锐意研究,结果发现:在具备支持体层与粘着剂层的贴附剂中,组合双氯芬酸或其可药用的盐、甘油、丁二醇及聚乙二醇单油酸酯而包含于上述粘着剂层中,并且将上述丁二醇与上述聚乙二醇单油酸酯的质量比设为特定的范围内,由此即便不含有产生皮肤刺激的丙二醇等,也可提高双氯芬酸的皮肤透过性。进而,本发明者等人发现这种贴附剂具有优异的附着性,剥离时的疼痛也充分地减少。
此外,先前,在上述专利文献1及专利文献5等中,报告有如果使贴附剂的粘着剂层中含有甘油与作为双氯芬酸的盐的双氯芬酸钠,则会促进双氯芬酸钠的分解、或双氯芬酸钠析出等,但本发明者等人惊奇地发现,通过将贴附剂的构成设为上述特定的构成,从而即便与双氯芬酸及其盐一并使用甘油,也可提高双氯芬酸的皮肤透过性,因而可获得含有甘油的皮肤刺激少的贴附剂。
进而,本发明者等人发现:在这种贴附剂中发挥的上述双氯芬酸的皮肤透过性提高效果明显优于分别单独使用上述丁二醇、或上述聚乙二醇单油酸酯的情形,是由以上述丁二醇与上述聚乙二醇单油酸酯成为特定的比率的方式组合上述双氯芬酸、上述甘油、上述丁二醇及上述聚乙二醇单油酸酯所产生的协同效果,从而完成本发明。
即,本发明的贴附剂的特征在于:
具备支持体层与粘着剂层,
上述粘着剂层含有双氯芬酸或其可药用的盐、甘油、丁二醇及聚乙二醇单油酸酯,并且上述丁二醇与上述聚乙二醇单油酸酯的质量比(丁二醇的质量∶聚乙二醇单油酸酯的质量)为1∶1~4∶1。
作为本发明的贴附剂,优选为上述丁二醇的含量相对于上述粘着剂层的总质量为4~18质量%,此外,优选为上述聚乙二醇单油酸酯的含量相对于上述粘着剂层的总质量为2.5~7.5质量%。
进而,作为本发明的贴附剂,优选为在上述粘着剂层中还含有亚硫酸钠。此外,优选为上述聚乙二醇单油酸酯中的氧化乙烯基的平均加成摩尔数为2~10,进而,优选为上述丁二醇为1,3-丁二醇。
发明的效果
根据本发明,可提供一种剥离时的疼痛减少,对皮肤的刺激少,双氯芬酸的皮肤透过性优异,并且附着性也优异的贴附剂。
具体实施方式
以下,对本发明结合其优选的实施方式详细地进行说明。
本发明的贴附剂具备支持体层与形成于上述支持体层的面上(通常为一面上)的粘着剂层,在上述粘着剂层中含有双氯芬酸或其可药用的盐、甘油、丁二醇及聚乙二醇单油酸酯。作为这种贴附剂,可列举在上述粘着剂层中含有水分的糊剂及在上述粘着剂层中不含水分的硬膏剂。作为本发明的贴附剂,就有与甘油等的相溶性优异,此外,通过含有的水分的作用而可期待对挫伤等急性疾病快速的冷却效果的倾向这样的观点而言,优选为糊剂。
本发明涉及的双氯芬酸为非类固醇系的具有镇痛、消炎作用的药物。作为上述双氯芬酸的形态,可为游离体,也可为其可药用的盐,也可为在制造中和/或所制造出的制剂中双氯芬酸的盐脱盐而成为游离体的形态,也可为它们中的1种,也可混合2种以上。其中,作为本发明涉及的双氯芬酸的形态,就有药物的稳定性提高,可抑制由酸所引起的对皮肤的刺激、粘着剂层的物性(强度、弹性、耐久性、粘着性及在贴附剂为糊剂的情形时的保水性)的降低的倾向这样的观点而言,优选为双氯芬酸的可药用的盐。作为上述双氯芬酸的可药用的盐,可列举钠盐、羟基乙基吡咯烷盐(epolamine,1-(2-羟基乙基)吡咯烷盐)、铵盐,其中优选为钠盐。
在本发明的贴附剂中,作为这种双氯芬酸及其可药用的盐的合计含量,可根据治疗的目的而适当调整,通常相对于上述粘着剂层的总质量为0.3~15质量%,就有双氯芬酸的皮肤透过性优异,并且可进一步抑制粘着剂层中的双氯芬酸的结晶析出的倾向这样的观点而言,优选为0.5~5质量%。
本发明的贴附剂通过在上述粘着剂层中含有甘油,而减少贴附剂对皮肤的刺激(发红、红斑、发疹、瘙痒感、疼痛等)。作为上述甘油的含量,优选为相对于上述粘着剂层的总质量为5~35质量%。在上述甘油的含量小于上述下限的情形时,有对皮肤的附着性、使用感降低的倾向,另一方面,在超过上述上限的情形时,有粘着剂层的保型性降低而使粘着剂层的成分渗出至支持体层、双氯芬酸的皮肤透过性降低、或以双氯芬酸为首的药物的保存稳定性降低而粘着剂层中的药物的含量减少的倾向。另外,先前报告有如果使贴附剂的粘着剂层中含有甘油与作为双氯芬酸的盐的双氯芬酸钠,则会促进双氯芬酸钠的分解、或双氯芬酸钠析出等,但在本发明中,即便与上述双氯芬酸及其盐一并使用上述甘油,也可显著地提高双氯芬酸的皮肤透过性,并且可充分地减少对皮肤的刺激。
作为本发明涉及的丁二醇,根据羟基的配置而可列举若干结构异构体,其中,就为医药制剂中通常使用的丁二醇这样的观点而言,优选为1,3-丁二醇。另外,上述1,3-丁二醇是几乎无臭的无色透明的粘性的液体。在本发明中,通过使上述丁二醇与其他本发明涉及的成分组合而包含于上述粘着剂层中,从而可提高双氯芬酸的皮肤透过性,并且也可提高附着性。
作为这种丁二醇的含量,优选为相对于上述粘着剂层的总质量为1~25质量%,更优选为4~18质量%。在上述丁二醇的含量小于上述下限的情形时,有双氯芬酸的皮肤透过性降低的倾向,另一方面,在超过上述上限的情形时,有双氯芬酸的皮肤透过性虽提高,但粘着剂层的保型性降低的倾向。
本发明涉及的聚乙二醇单油酸酯为聚乙二醇的单油酸酯。在本发明中,使上述聚乙二醇单油酸酯与其他本发明涉及的成分组合而包含于上述粘着剂层中,由此无需配合例如己二酸二异丙酯那样的具有溶解作用的成分。在上述聚乙二醇单油酸酯中,作为聚乙二醇链中的氧化乙烯基的平均加成摩尔数,优选为2~20。在上述氧化乙烯基的平均加成摩尔数小于上述下限的情形时,有聚乙二醇单油酸酯的亲油性变强的倾向,另一方面,在超过上述上限的情形时,有亲水性变强的倾向。此外,其中,就上述亲油性与亲水性的平衡更优选这样的观点而言,作为上述氧化乙烯基的平均加成摩尔数,更优选为2~10,进而就易于容易地购得这样的观点而言,进而优选为6或10,特别优选为6。另外,上述氧化乙烯基的平均加成摩尔数可通过NMR测定而求出。
作为这种聚乙二醇单油酸酯的含量,优选为相对于上述粘着剂层的总质量为0.5~10质量%,更优选为2.5~7.5质量%。在上述聚乙二醇单油酸酯的含量小于上述下限的情形时,有双氯芬酸的皮肤透过性降低的倾向,另一方面,在超过上述上限的情形时,有对皮肤的刺激增大、或产生聚乙二醇单油酸酯分离而在粘着剂层的表面渗出的渗出现象从而降低对皮肤的附着性的倾向。
此外,在本发明涉及的粘着剂层中,作为上述丁二醇与上述聚乙二醇单油酸酯的质量比(丁二醇的质量∶聚乙二醇单油酸酯的质量),需要为1∶1~4∶1,特别优选为1.25∶1~4∶1。在本发明中,在使用了无毛小鼠的皮肤的皮肤透过试验中,双氯芬酸的自试验开始至12小时后的累计皮肤透过量优选为8μg/cm2/12hr以上,但在上述丁二醇的质量相对于上述聚乙二醇单油酸酯的质量的比率小于上述下限的情形时,上述累计皮肤透过量减少,即双氯芬酸的皮肤透过性降低。另一方面,在超过上述上限的情形时,上述累计皮肤透过量增加,即双氯芬酸的皮肤透过性提高,但粘着剂层的保型性降低。
进而,在本发明涉及的粘着剂层中,作为上述丁二醇与上述聚乙二醇单油酸酯的合计含量,可根据上述双氯芬酸的量而适当调整,优选为相对于上述粘着剂层的总质量为1.5~35质量%,更优选为5~25质量%。在上述合计含量小于上述下限的情形时,有双氯芬酸的皮肤透过性降低的倾向,另一方面,在超过上述上限的情形时,有粘着剂层的保型性降低而使粘着剂层的成分渗出至支持体层,或双氯芬酸的皮肤透过性降低,或对皮肤的刺激增大,或产生丁二醇分离而在粘着剂层的表面渗出的渗出现象从而降低对皮肤的附着性的倾向。
作为本发明的贴附剂,优选为在上述粘着剂层中还含有亚硫酸钠。本发明者等人发现,如果在贴附剂的粘着剂层中含有上述聚乙二醇单油酸酯,则粘着剂层随着时间经过而逐渐变色成褐色,因此进一步反复进行锐意研究,结果发现:通过在上述粘着剂层中还含有亚硫酸钠,可充分抑制上述粘着剂层的变色。
作为上述亚硫酸钠,例如可列举具有7个结晶水的亚硫酸钠(晶体)、无水的干燥亚硫酸钠等,其中优选为干燥亚硫酸钠。在使上述粘着剂层中含有这种亚硫酸钠的情形时,其含量优选为相对于上述粘着剂层的总质量为0.01~1质量%,更优选为0.01~0.25质量%。此外,在不使上述粘着剂层中含有下述焦亚硫酸钠和/或亚硫酸氢钠的情形时,进而优选为0.02~0.25质量%,特别优选为0.03~0.2质量%。在上述亚硫酸钠的含量小于上述下限的情形时,有变得难以充分抑制上述粘着剂层的变色的倾向,另一方面,在超过上述上限的情形时,虽根据其含量而提高抑制上述变色的效果,但有难闻的腐臭变强、或粘着剂层的保型性降低而使粘着剂层的成分渗出至支持体层的倾向。
此外,作为本发明的贴附剂,也优选为在上述粘着剂层中除上述亚硫酸钠外也含有焦亚硫酸钠和/或亚硫酸氢钠。在使上述粘着剂层中含有上述焦亚硫酸钠和/或亚硫酸氢钠的情形时,上述亚硫酸钠的含量优选为相对于上述粘着剂层的总质量为0.01~0.4质量%,更优选为0.01~0.04质量%。此外,作为上述焦亚硫酸钠及上述亚硫酸氢钠的合计含量,优选为相对于上述粘着剂层的总质量为0.01~0.4质量%。在上述亚硫酸钠、焦亚硫酸钠及亚硫酸氢钠的含量小于上述下限的情形时,有变得难以充分地抑制上述粘着剂层的变色的倾向,另一方面,在超过上述上限的情形时,虽根据其含量而提高抑制上述变色的效果,但有难闻的腐臭变强的倾向。
在本发明的贴附剂为糊剂的情形时,作为本发明涉及的粘着剂层(膏体层),优选为还含有水、水溶性高分子,也可视需要含有交联剂等。作为上述水,优选为实施过离子交换、蒸馏、过滤等纯化的水,例如可优选地使用日本药典(第十五次修改版日本药典)中记载的“纯化水”。作为上述水的含量,优选为相对于上述粘着剂层(膏体层)的总质量为15~75质量%。在上述水的含量在上述范围外的情形时,有变得难以在粘着剂层(膏体层)中维持优选的凝胶物性(强度、弹性、耐久性、粘着性、保水性等)的倾向。
作为上述水溶性高分子,可列举聚丙烯酸部分中和物、聚丙烯酸完全中和物、聚丙烯酸、羧基乙烯基聚合物、羧基甲基纤维素、羧基甲基纤维素钠、甲基纤维素、乙基纤维素、羟基乙基纤维素、羟基丙基纤维素、明胶、酪蛋白、支链淀粉、琼脂、葡聚糖、糊精、海藻酸钠、可溶性淀粉、羧化淀粉、聚乙烯醇、聚环氧乙烷、聚丙烯酰胺、聚乙烯基吡咯烷酮、聚乙烯基醚-顺丁烯二酸酐共聚物、甲氧基乙烯-顺丁烯二酸酐共聚物、异丁烯-顺丁烯二酸酐共聚物、聚乙烯亚胺等,可单独使用它们中的1种,也可组合2种以上使用。作为上述水溶性高分子,就可获得作为糊剂的优选凝胶物性(强度、弹性、耐久性、粘着性、保水性等),此外,就对皮肤的附着性进一步提高的倾向这样的观点而言,优选为聚丙烯酸完全中和物、羟基丙基纤维素、羧基甲基纤维素钠、明胶。作为这种水溶性高分子的合计含量,就获得更优选的凝胶物性的倾向这样的观点而言,优选为相对于上述粘着剂层(膏体层)的总质量为5~20质量%。
上述交联剂具有通过交联上述水溶性高分子而将上述粘着剂层(膏体层)凝胶化并保型的作用。作为这种交联剂,并无特别限制,例如可列举硫酸铝钾、氯化钙、氯化镁、氢氧化铝、氨基乙酸二羟基铝、硅酸铝镁,可单独使用这些中的1种,也可组合2种以上使用。在使上述粘着剂层(膏体层)中含有上述交联剂的情形时,作为其合计含量,就有可获得优选的凝胶物性(强度、弹性、耐久性、粘着性、保水性等)的倾向这样的观点而言,优选为相对于上述粘着剂层(膏体层)的总质量为0.1~5质量%。
此外,在本发明的贴附剂为硬膏剂的情形时,作为本发明涉及的粘着剂层,优选为还含有粘着剂,也可视需要含有粘着赋予剂及软化剂等。作为上述粘着剂,就粘着性优异,药物的释放性优异这样的观点而言,可列举丙烯酸系粘着剂、苯乙烯嵌段共聚物系粘着剂,可单独使用这些中的1种,也可组合2种以上使用。
作为上述丙烯酸系粘着剂,可列举使(甲基)丙烯酸、(甲基)丙烯酸-2-乙基己酯、(甲基)丙烯酸甲酯、(甲基)丙烯酸丁酯、(甲基)丙烯酸羟基乙酯等(甲基)丙烯酸单体中的至少1种聚合或共聚而成的粘着剂。作为这种丙烯酸系粘着剂,优选为丙烯酸-2-乙基己酯/乙酸乙烯酯共聚物、丙烯酸-2-乙基己酯/乙酸乙烯酯/丙烯酸共聚物、丙烯酸-2-乙基己酯/乙酸乙烯酯/丙烯酸羟基乙酯共聚物、丙烯酸-2-乙基己酯/乙酸乙烯酯/丙烯酸羟基乙酯/丙烯酸共聚物、丙烯酸-2-乙基己酯/甲基丙烯酸-2-乙基己酯/甲基丙烯酸十二烷基酯共聚物等,更优选为丙烯酸-2-乙基己酯/乙酸乙烯酯共聚物、丙烯酸-2-乙基己酯/乙酸乙烯酯/丙烯酸共聚物。
作为上述苯乙烯嵌段共聚物,可列举苯乙烯-异戊二烯-苯乙烯嵌段共聚物(SIS)、苯乙烯-丁二烯-苯乙烯嵌段共聚物(SBS)、苯乙烯-乙烯-丁烯-苯乙烯嵌段共聚物(SEBS)或苯乙烯-乙烯-丙烯-苯乙烯嵌段共聚物(SEPS)等,其中,优选为苯乙烯-异戊二烯-苯乙烯嵌段共聚物(SIS)。
作为上述粘着赋予剂,可列举脂环族饱和烃树脂、松香或松香衍生物(例如松香的甘油酯、氢化松香、氢化松香的甘油酯或松香的季戊四醇酯等)、萜烯树脂、石油树脂、顺丁烯二酸树脂等,其中,优选为脂环族饱和烃树脂、氢化松香的甘油酯。作为这种粘着赋予剂,可单独使用1种,也可组合2种以上使用。
作为上述软化剂,可列举石油系油(例如烷烃系加工油、环烷系加工油或芳香族系加工油等)、角鲨烷、角鲨烯、植物系油(例如杏仁油、橄榄油、茶树油、蓖麻油、浮油或花生油等)、饱和或不饱和脂肪酸、硅油、二元酸酯(例如邻苯二甲酸二丁酯或邻苯二甲酸二辛酯等)、液状橡胶(例如聚丁烯或液状异戊二烯橡胶等)、液状脂肪酸酯(肉豆蔻酸异丙酯、月桂酸己酯、癸二酸二乙酯或癸二酸异丙酯等)、二甘醇、乙二醇水杨酸酯、双丙甘醇、甘油三乙酸酯、柠檬酸三乙酯或克罗米通等,可单独使用它们中的1种,也可组合2种以上使用。此外,作为上述软化剂,就有对皮肤的附着性进一步提高的倾向这样的观点而言,优选为液态石蜡和/或肉豆蔻酸异丙酯。
此外,作为本发明涉及的粘着剂层,也可在不阻碍本发明的效果的范围内,还含有除上述甘油及上述丁二醇以外的多元醇、pH值调节剂、防腐剂、抗氧化剂及其他添加剂。
作为上述多元醇,可列举除上述甘油及上述丁二醇以外的醇,例如可列举丙二醇、聚乙二醇、D-山梨糖醇等,可单独使用它们中的1种,也可组合2种以上使用。在使上述粘着剂层中含有这种多元醇的情形时,作为其合计含量,就有可平衡良好地在粘着剂层中保持优选的保湿性、优选的药物溶解性及优选的粘着性的倾向这样的观点而言,优选为相对于上述粘着剂层的总质量为60质量%以下,更优选为15~60质量%。此外,就使用这些多元醇中的丙二醇的情形时有双氯芬酸的溶解性、皮肤透过性虽提高,但对皮肤的刺激增加的倾向这样的观点而言,特别优选为相对于上述粘着剂层的总质量为10质量%以下。另外,就使粘着剂层中含有这些多元醇中的山梨糖醇的情形时存在贴附剂的稳定性降低的情形这样的观点而言,优选为不配合山梨糖醇。
上述pH值调节剂具有调整药物的皮肤透过速度、贴附剂对皮肤的刺激的作用及在本发明的贴附剂为糊剂的情形时具有调整交联速度的作用。作为这种pH值调节剂,例如可列举:乙酸、乳酸、草酸、柠檬酸、酒石酸、乙二胺四乙酸等有机酸;盐酸、硫酸、硝酸、磷酸等无机酸;以及上述有机酸及上述无机酸的可药用的盐,可单独使用它们中的1种,也可组合2种以上使用。在使上述粘着剂层中含有上述pH值调节剂的情形时,作为其合计含量,可根据目标pH值而适当调整,就有可获得优选的粘着剂层的物性(强度、弹性、耐久性、粘着性及在贴附剂为糊剂的情形时的保水性)的倾向这样的观点而言,优选为相对于上述粘着剂层的总质量为0.05~2质量%。另外,在本发明的贴附剂为糊剂的情形时,作为上述粘着剂层的pH值,就有药物的皮肤透过性提高,制剂的保存稳定性提高,进而成为优选的交联速度的倾向这样的观点而言,优选为5.5~8.0。另外,此处所谓的pH值是指在95质量份的纯化水中悬浮5质量份的粘着剂层并利用复合玻璃电极测定该悬浮液而得的值。
作为上述防腐剂,可列举对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯、对羟基苯甲酸丁酯、1,2-戊二醇、苯甲酸及其盐、水杨酸及其盐、山梨酸及其盐、去氢乙酸及其盐、4-异丙基-3-甲基苯酚、2-异丙基-5-甲基苯酚、苯酚、桧木醇、甲酚、2,4,4'-三氯-2'-羟基二苯醚、3,4,4'-三氯均二苯脲、氯丁醇、烷基二甲基苄基氯化铵、苄乙铵等,可单独使用它们中的1种,也可组合2种以上使用。在使上述粘着剂层中含有上述防腐剂的情形时,作为其合计含量,就有发挥优选的防腐效果的倾向这样的观点而言,优选为相对于上述粘着剂层的总质量为0.005~1质量%。
作为上述抗氧化剂,可列举丁基羟基苯甲醚、二丁基羟基甲苯、降二氢愈创木酸、生育酚、乙酸生育酚、柠檬酸、乙二胺四乙酸、抗坏血酸、没食子酸丙酯等,可单独使用它们中的1种,也可组合2种以上使用。在使上述粘着剂层中含有上述抗氧化剂的情形时,作为其合计含量,就有发挥优选的抗氧化效果的倾向这样的观点而言,优选为相对于上述粘着剂层的总质量为0.001~5质量%。
作为上述其他添加剂,例如可列举:氧化钛、硅酸铝、轻质二氧化硅、高岭土等无机填充剂;薄荷醇;包含甲基丙烯酸氨基烷基酯共聚物E等丙烯酸酯共聚物的粘着增强剂等,可单独使用它们中的1种,也可组合2种以上使用。
本发明涉及的粘着剂层是含有上述成分的层,可为由1种组成所构成的单层,也可为叠层组成不同的多个层而成的复层。作为这种粘着剂层的厚度,就双氯芬酸的皮肤透过性更优异这样的观点而言,优选为250~1500μm。
作为本发明涉及的支持体层的材质,可列举:聚乙烯、聚丙烯、乙烯-乙酸乙烯酯共聚物、氯乙烯、聚氨酯、聚对苯二甲酸乙二酯、聚对苯二甲酸丁二酯等聚酯;尼龙等聚酰胺;嫘萦、纸浆、棉等纤维素或其衍生物;聚丙烯腈;可单独使用它们中的1种,也可组合2种以上使用。作为本发明涉及的支持体层,优选为使用包含上述材质的纤维的布帛,作为上述布帛,更优选为使用通过编织、缠绕、热融接、压接或者粘合剂粘接等方法而对上述纤维进行加工而成的织布、不织布。
作为这种支持体层,例如优选为使用包含聚酯纤维的不织布,作为上述不织布的目付,更优选为50~200g/m2。在上述不织布的目付小于上述下限的情形时,有产生剥离贴附剂时容易破裂等强度方面的问题、或产生由粘着剂层所含有的成分在支持体层的背面渗出而导致贴附剂的外观、使用感的恶化等问题的倾向。另一方面,在超过上述上限的情形时,有支持体层的伸缩性、柔软性不足,因而贴附剂变得容易剥离的倾向。
作为本发明的贴附剂,为了直至使用贴附剂时被覆上述粘着剂层的表面而进行保护,也可进而具备剥离衬垫层。作为上述剥离衬垫层的材质,并无特别限制,可列举:聚乙烯、聚丙烯、乙烯-乙酸乙烯酯共聚物、乙烯-乙烯醇共聚物、氯乙烯、聚氨酯、聚对苯二甲酸乙二酯、聚对苯二甲酸丁二酯、聚萘二甲酸乙二酯等聚酯;尼龙等聚酰胺;聚丙烯腈;纤维素或其衍生物;铝等的金属箔,可单独使用它们中的1种,也可组合2种以上使用。作为上述剥离衬垫层,可列举包含上述材质的膜,作为这种膜,也可为预先对与上述粘着剂层接触的面实施有机硅处理或氟树脂处理等以增强其脱模性的膜。作为上述剥离衬垫层,优选为使用包含聚对苯二甲酸乙二酯、聚丙烯的膜。此外,作为这种剥离衬垫层的厚度,优选为20~150μm。
本发明的贴附剂并无特别限制,可通过适当采用公知的贴附剂的制造方法而制造,例如在制造糊剂作为本发明的贴附剂的情形时,可通过以下的方法制造。首先,根据常用方法混练上述双氯芬酸或其可药用的盐、上述甘油、上述丁二醇、上述聚乙二醇单油酸酯、上述水、上述水溶性高分子及视需要混练上述添加剂等而获得均匀的粘着剂层组成物。接着,将该粘着剂层组成物以特定的厚度涂布至上述支持体层的面上(通常为一面上)而形成粘着剂层。接着,在上述粘着剂层的与上述支持体层相反的面上贴合上述剥离衬垫层,并裁剪成特定的形状,由此获得本发明的贴附剂。或者,也可首先将上述粘着剂层组成物以特定的厚度涂布至上述剥离衬垫层的一面上而形成粘着剂层后,在上述粘着剂层的与上述剥离衬垫层相反的面上贴合上述支持体层,并裁剪成特定的形状,由此获得本发明的贴附剂。
实施例
以下,基于实施例及比较例更具体地说明本发明,但本发明并不限定于以下的实施例。另外,各实施例及比较例中获得的贴附剂中,皮肤透过试验、粘着力试验(滚球粘性试验)、保型性评价试验、附着性评价试验、剥离时疼痛评价试验、稳定性评价试验及经时着色评价试验通过以下所示的方法进行。
(皮肤透过试验)
首先,剥离无毛小鼠的背部皮肤,以其真皮侧成为接受器槽侧的方式安装于使37℃的温水于外周部循环的弗朗兹型流通单元。接着,在该皮肤的角质层侧贴附切断成4.5cm2的大小并去除剥离衬垫层的贴附剂。使磷酸缓冲溶液(pH值为7.4)以5mL/hr的流量在上述流通单元的接收器槽内流动,每隔4小时自接收器槽收取测定开始起至12小时的试料液,对收取的各试料液通过高效液相色谱法测定药物(双氯芬酸)的浓度。根据所获得的测定值,通过以下的式子:
F(μg/cm2/hr)=[药物浓度(μg/ml)×流量(ml)]/贴附剂面积(cm2)/时间(hr)
算出每小时的药物的皮肤透量(F;μg/cm2/hr),并将所获得的药物透过量乘以12小时,由此求出测定开始起至12小时的药物的累计皮肤透过量(μg/cm2/12hr)。此外,通过将所获得的药物透过量乘以24小时,而求出测定开始起至24小时的药物的累计皮肤透过量(μg/cm2/24hr)。累计皮肤透过量的值较大的制剂认定为药物的皮肤透过性优异。
(滚球粘性试验)
通过NichibanRollingBall法(“接着便览”第14版,高分子刊行会发行,1985年)进行测定。即,以去除了剥离衬垫层的贴附剂的粘着剂层成为上表面的方式配置于包含正弦曲线的倾斜台下的水平的底部,使20号钢球(直径为20/32英寸)在倾斜台的倾斜面上滚动,测定球在粘着剂层上停止的距离,将该距离设为球停止距离。另外,球停止距离较短的制剂认定为附着性优异。
(保型性评价试验)
在以手指轻轻碰触去除了剥离衬垫层的贴附剂的粘着剂层的表面后,抽离手指,基于以下的基准进行评价:
A:在抽离手指时,粘着剂层未变形而保持形状
B:在抽离手指时,粘着剂层的一部分变形并剥离。
(附着性评价试验)
对健康成人男女(30名)在各肘部贴附贴附剂,将肘伸屈40次后,基于以下的基准进行评价:
得分1:贴附剂的面积的约1/2以上剥离
得分2:贴附剂的面积的约1/3以上且小于1/2剥离
得分3:贴附剂的面积的约1/4以上且小于1/3剥离
得分4:仅贴附剂的端的部分剥离
得分5:贴附剂完全无剥离的部分
求出得分的平均值,将其设为初始附着性。
此外,对健康成人男女(30名)在各肘部贴附贴附剂,在12小时后,基于以下的基准进行评价:
得分1:贴附剂脱落而未附着
得分2:贴附剂的面积的约1/2以上剥离
得分3:贴附剂的面积的约1/3以上且小于1/2剥离
得分4:仅贴附剂的端的部分剥离
得分5:贴附剂完全无剥离的部分
求出得分的平均值,将其设为12小时附着性。
(剥离时疼痛评价试验)
对健康成人男女(30名)在各肘部贴附贴附剂,在12小时后将其剥离,基于以下的基准进行评价:
得分1:极大的疼痛(感觉到极强烈疼痛)
得分2:非常痛(感觉到强烈疼痛)
得分3:较痛(感觉到疼痛)
得分4:略痛(感觉到较弱的疼痛)
得分5:无痛(未特别感觉到疼痛)
求出得分的平均值,将其设为剥离时疼痛评价。
(稳定性评价试验)
将贴附剂封入铝包装材中,在温度60℃、湿度75%的恒温恒湿器内静置,经过1个月后取出贴附剂,并通过高效液相色谱法求出药物(双氯芬酸钠)的含量(残留质量)。此外,对刚制造后的贴附剂也同样地通过高效液相色谱法求出药物的含量(初始质量),并通过下式:(残留质量/初始质量)×100求出双氯芬酸钠残留量(质量%)。另外,双氯芬酸钠残留量较多的制剂认定为稳定性优异。
(经时着色评价试验)
首先,将贴附剂分别在50℃及60℃下各静置并保存15天(0.5个月)。接着,使用利用标准白色板校正了的色彩色差计(商品名:CR-200,MinoltaCamera公司制造),自保存前的贴附剂的脱模衬垫侧抵接测定探针而求出L*a*b*表色系统中的坐标(L,a,b)。此外,也同样地分别对以各温度条件保存后的贴附剂求出坐标(L',a',b'),并通过以下的式子:
ΔE=((L-L')2+(a-a')2+(b-b')2)1/2
分别算出保存前的贴附剂与保存后的各贴附剂的色差(ΔE)。另外,通常如果ΔE的值超过1.5,则在目测时也可发现颜色的不同。以下表示ΔE的值与利用目测的辨识的通常的关系供参考。
(实施例1)
首先,分别称取5.0质量份的甘油、35.0质量份的D-山梨糖醇水溶液(70质量%)、10.0质量份的丁二醇(1,3-丁二醇)、5.0质量份的聚乙二醇单油酸酯(氧化乙烯基的平均加成摩尔数:6)、1.0质量份的双氯芬酸钠、0.5质量份的薄荷醇、7.0质量份的水溶性高分子1(聚丙烯酸钠质量:羧基甲基纤维素钠质量=5:2)、0.5质量份的粘着增强剂、6.0质量份的无机填充剂、0.44质量份的交联剂、0.25质量份的pH值调节剂、0.02质量份的亚硫酸钠、0.02质量份的二丁基羟基甲苯及29.27质量份的纯化水并加以混合,获得粘着剂层(膏体层)组成物。接着,将所获得的粘着剂层组成物以成为1000g/m2的方式在包含聚酯纤维的不织布(目付:100g/m2)的一面上延展后,利用聚丙烯制的剥离衬垫层覆盖上述粘着剂层组成物的涂布面,并裁剪成特定的大小(10cm×14cm)而获得贴附剂(糊剂)。将对所获得的贴附剂进行皮肤透过试验(12小时)及滚球粘性试验的结果与粘着剂层组成物的组成一并示于表1。
(比较例1~17)
除将粘着剂层组成物的组成分别设为表1~3所示的组成以外,以与实施例1同样的方式获得贴附剂(糊剂)。将对所获得的贴附剂进行皮肤透过试验(12小时)及滚球粘性试验的结果与粘着剂层组成物的组成一并分别示于表1~3。另外,表1~3所记载的各化合物分别如下。
POE(9)月桂基醚:聚氧乙烯月桂基醚(氧化乙烯基的平均加成摩尔数:9)
POE(2)油基醚:聚氧乙烯油基醚(氧化乙烯基的平均加成摩尔数:2)
POE(20)失水山梨糖醇单油酸酯:聚氧乙烯失水山梨糖醇单油酸酯(氧化乙烯基的平均加成摩尔数:20)
POE(7)油基醚:聚氧乙烯油基醚(氧化乙烯基的平均加成摩尔数:7)
POE(20)失水山梨糖醇三油酸酯:聚氧乙烯失水山梨糖醇三油酸酯(氧化乙烯基的平均加成摩尔数:20)
聚乙二醇(10)单月桂酸酯:聚乙二醇单月桂酸酯(氧化乙烯基的平均加成摩尔数:10)。
[表1]
[表2]
[表3]
根据表1所示的结果可明确确认:本发明的贴附剂含有甘油,此外,虽然不含有引起皮肤刺激的丙二醇等,但双氯芬酸的皮肤透过性也明显优异。另一方面,确认了如果代替丙二醇(比较例1)而配合其他保湿剂(比较例2~6),则有双氯芬酸的累计皮肤透过量降低的倾向,尤其是在仅使用甘油来代替丙二醇的情形时(比较例2),双氯芬酸的累计皮肤透过量大幅降低。此外,确认了在仅使用丁二醇来代替丙二醇的情形时(比较例3),双氯芬酸的累计皮肤透过量不会提高。另外,比较例3中所获得的贴附剂的己二酸二异丙酯的臭味强,难以用作制剂。进而,根据表2~3所示的结果可明确确认:不含有本发明涉及的丁二醇而仅使用溶解剂的情形(比较例7~17)时,即便在使用了聚乙二醇单油酸酯的情形时(比较例7~8),双氯芬酸的累计皮肤透过量也不会提高。由此,可确认在本发明的贴附剂中发挥的双氯芬酸的皮肤透过性的提高效果为协同效果。
(实施例2~6)
除将粘着剂层组成物的组成分别设为表4所示的组成以外,以与实施例1同样的方式获得贴附剂(糊剂)。将对所获得的贴附剂进行皮肤透过试验(12小时)、滚球粘性试验及经时着色评价试验的结果与粘着剂层组成物的组成一并分别示于表4。另外,表4中记载的水溶性高分子2以5∶1.25∶2∶3的质量比依次含有聚丙烯酸钠、羧基甲基纤维素钠、明胶及羟基丙基纤维素。
[表4]
根据表4所示的结果可明确确认:在大量地含有亚硫酸钠的贴附剂(实施例2)、含有亚硫酸钠与焦亚硫酸钠或亚硫酸氢钠的贴附剂(实施例3~4)中,尤其是可抑制粘着剂层的变色。
(实施例7~19、比较例18~19)
除将粘着剂层组成物的组成分别设为表5~6所示的组成以外,以与实施例1同样的方式获得贴附剂(糊剂)。将对实施例7~9、比较例18~19中所获得的贴附剂进行皮肤透过试验(12小时)、滚球粘性试验及保型性评价试验的结果与粘着剂层组成物的组成一并分别示于表5。此外,在表5中也一并表示实施例2的结果。进而,将对实施例10~19中所获得的贴附剂进行滚球粘性试验的结果与粘着剂层组成物的组成一并分别示于表6。
[表5]
[表6]
根据表5所示的结果可明确确认:在丁二醇的质量相对于聚乙二醇单油酸酯的质量的比率低的贴附剂(比较例18)中,双氯芬酸的皮肤透过性未充分提高。此外,丁二醇的质量相对于聚乙二醇单油酸酯的质量的比率多的贴附剂(比较例19)中,粘着剂层的保型性差而难以用作贴附剂。
此外,将对比较例1、实施例2~3、8及10~15中所获得的贴附剂进行皮肤透过试验(24小时)、附着性评价试验、剥离时疼痛评价试验及稳定性评价试验的结果示于表7。
[表7]
根据表7所示的剥离时疼痛评价试验的结果可明确确认:本发明的贴附剂的剥离时的疼痛充分地减少了。此外,通过皮肤透过试验(24小时)及附着性试验,也确认了本发明的贴附剂具有优异的皮肤透过性及附着性。进而,确认了本发明的贴附剂的稳定性优异,可充分抑制药物的分解。
产业上的可利用性
如以上说明,根据本发明,可提供一种剥离时的疼痛减少,对皮肤的刺激少,双氯芬酸的皮肤透过性优异,并且附着性也优异的贴附剂。
Claims (6)
1.一种贴附剂,其具备支持体层与粘着剂层,
该贴附剂是在所述粘着剂层中含有相对于所述粘着剂层的总质量为15~75质量%水分的糊剂,
所述粘着剂层含有双氯芬酸或其可药用的盐、甘油、丁二醇及聚乙二醇单油酸酯,并且所述丁二醇与所述聚乙二醇单油酸酯的质量比即丁二醇的质量∶聚乙二醇单油酸酯的质量为1∶1~4∶1,
并且,所述粘着剂层不含有丙二醇。
2.如权利要求1所述的贴附剂,所述丁二醇的含量相对于所述粘着剂层的总质量为4~18质量%。
3.如权利要求1或2所述的贴附剂,所述聚乙二醇单油酸酯的含量相对于所述粘着剂层的总质量为2.5~7.5质量%。
4.如权利要求1或2所述的贴附剂,所述粘着剂层中还含有亚硫酸钠。
5.如权利要求1或2所述的贴附剂,所述聚乙二醇单油酸酯中的氧化乙烯基的平均加成摩尔数为2~10。
6.如权利要求1或2所述的贴附剂,所述丁二醇为1,3-丁二醇。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011267470 | 2011-12-07 | ||
JP2011-267470 | 2011-12-07 | ||
PCT/JP2012/081657 WO2013084995A1 (ja) | 2011-12-07 | 2012-12-06 | 貼付剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103974700A CN103974700A (zh) | 2014-08-06 |
CN103974700B true CN103974700B (zh) | 2015-12-09 |
Family
ID=48574350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280060286.1A Active CN103974700B (zh) | 2011-12-07 | 2012-12-06 | 贴附剂 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20140322300A1 (zh) |
EP (1) | EP2789335B1 (zh) |
JP (1) | JP5576573B2 (zh) |
KR (1) | KR101890011B1 (zh) |
CN (1) | CN103974700B (zh) |
BR (1) | BR112014013878B1 (zh) |
ES (1) | ES2620878T3 (zh) |
TW (1) | TWI572373B (zh) |
WO (1) | WO2013084995A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102094586B1 (ko) * | 2014-12-22 | 2020-03-27 | 히사미쓰 세이야꾸 가부시키가이샤 | 파프제 |
WO2017014306A1 (ja) * | 2015-07-22 | 2017-01-26 | 積水化学工業株式会社 | 製剤 |
EP3645602B1 (en) * | 2017-11-06 | 2023-06-07 | BestHealth4U, Lda | Adhesion materials and methods of manufacture |
EP3760198B1 (en) * | 2018-02-27 | 2023-09-06 | Hisamitsu Pharmaceutical Co., Inc. | Diclofenac-containing emulsified gel composition |
JP7202441B2 (ja) * | 2019-02-18 | 2023-01-11 | 久光製薬株式会社 | 冷却シート |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0656660A (ja) * | 1992-07-31 | 1994-03-01 | Nippon Saafuakutanto Kogyo Kk | ジクロフェナクナトリウム含有貼付剤 |
JPH08319213A (ja) * | 1995-05-23 | 1996-12-03 | Pacific Corp | 美容及び医療用の粘着性パックシート |
JP2001064161A (ja) * | 1999-08-30 | 2001-03-13 | Lion Corp | 貼付剤 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6160608A (ja) * | 1984-08-30 | 1986-03-28 | Taisho Pharmaceut Co Ltd | ジクロフェナック湿布剤 |
JPS6391318A (ja) | 1986-10-03 | 1988-04-22 | Teikoku Seiyaku Kk | ジクロフエナクナトリウム含有貼付剤 |
JPH03109327A (ja) * | 1989-09-22 | 1991-05-09 | Maeda Yakuhin Kogyo Kk | 消炎鎮痛外用貼付剤 |
JPH07121860B2 (ja) | 1989-09-22 | 1995-12-25 | エスエス製薬株式会社 | 外用薬剤組成物 |
WO1993000873A1 (en) * | 1991-07-03 | 1993-01-21 | Sano Corporation | Composition and method for transdermal delivery of diclofenac |
US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
JP4275751B2 (ja) | 1996-12-27 | 2009-06-10 | 久光製薬株式会社 | 外用組成物 |
TW450810B (en) * | 1997-02-20 | 2001-08-21 | Fujisawa Pharmaceutical Co | Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases |
KR20020012978A (ko) * | 2000-08-10 | 2002-02-20 | 이영길 | 진통소염 효과를 갖는 디클로페낙염을 함유 카타플라스마제 |
JP2002193793A (ja) | 2000-12-26 | 2002-07-10 | Teikoku Seiyaku Co Ltd | 非ステロイド系消炎鎮痛貼付剤 |
US7473432B2 (en) * | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
US20110071204A1 (en) * | 2005-02-03 | 2011-03-24 | Kyorin Pharmaceutical Co., Ltd. | Percutaneous absorption preparation |
PL1872796T3 (pl) * | 2005-02-25 | 2012-01-31 | Hisamitsu Pharmaceutical Co | Preparat przezskórny do stosowania zewnętrznego zawierający niesteroidowy lek przeciwzapalny/przeciwbólowy |
JP5020554B2 (ja) * | 2006-06-29 | 2012-09-05 | ライオン株式会社 | 非水系粘着剤組成物とこれを用いた貼付剤 |
WO2008001200A2 (en) * | 2006-06-29 | 2008-01-03 | Antares Pharma Ipl Ag | Transdermal composition having enhanced color stability |
JP4526598B2 (ja) * | 2007-08-29 | 2010-08-18 | 祐徳薬品工業株式会社 | 乳化型外用剤およびその製造方法 |
US20120004306A1 (en) * | 2009-03-11 | 2012-01-05 | Kowa Co., Ltd. | External preparation containing analgesic/anti-inflammatory agent |
-
2012
- 2012-12-06 KR KR1020147018424A patent/KR101890011B1/ko active IP Right Grant
- 2012-12-06 CN CN201280060286.1A patent/CN103974700B/zh active Active
- 2012-12-06 WO PCT/JP2012/081657 patent/WO2013084995A1/ja active Application Filing
- 2012-12-06 US US14/363,559 patent/US20140322300A1/en not_active Abandoned
- 2012-12-06 EP EP12854655.3A patent/EP2789335B1/en active Active
- 2012-12-06 ES ES12854655.3T patent/ES2620878T3/es active Active
- 2012-12-06 JP JP2013548293A patent/JP5576573B2/ja active Active
- 2012-12-06 BR BR112014013878-8A patent/BR112014013878B1/pt active IP Right Grant
- 2012-12-07 TW TW101146258A patent/TWI572373B/zh active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0656660A (ja) * | 1992-07-31 | 1994-03-01 | Nippon Saafuakutanto Kogyo Kk | ジクロフェナクナトリウム含有貼付剤 |
JPH08319213A (ja) * | 1995-05-23 | 1996-12-03 | Pacific Corp | 美容及び医療用の粘着性パックシート |
JP2001064161A (ja) * | 1999-08-30 | 2001-03-13 | Lion Corp | 貼付剤 |
Also Published As
Publication number | Publication date |
---|---|
TW201328730A (zh) | 2013-07-16 |
US20140322300A1 (en) | 2014-10-30 |
JP5576573B2 (ja) | 2014-08-20 |
ES2620878T3 (es) | 2017-06-30 |
KR101890011B1 (ko) | 2018-08-20 |
CN103974700A (zh) | 2014-08-06 |
TWI572373B (zh) | 2017-03-01 |
BR112014013878A8 (pt) | 2017-06-13 |
BR112014013878A2 (pt) | 2017-06-13 |
EP2789335A4 (en) | 2015-07-22 |
EP2789335A1 (en) | 2014-10-15 |
EP2789335B1 (en) | 2017-02-15 |
BR112014013878B1 (pt) | 2021-12-07 |
WO2013084995A1 (ja) | 2013-06-13 |
JPWO2013084995A1 (ja) | 2015-04-27 |
KR20140099318A (ko) | 2014-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103974700B (zh) | 贴附剂 | |
CN102791267B (zh) | 消炎镇痛外用贴剂 | |
CN104379139A (zh) | 贴附剂 | |
CN104487071A (zh) | 贴附剂 | |
ES2705028T3 (es) | Yeso a base de agua | |
JP6142379B2 (ja) | 含水貼付剤 | |
US9700522B2 (en) | Transdermal patch and method for delivery of vitamin B12 | |
CN111615381A (zh) | 水凝胶贴剂形式的用于经皮施用的药物组合物 | |
TW201330878A (zh) | 含有羅匹尼羅(ropinirole)之貼附劑 | |
JP5421063B2 (ja) | ジクロフェナクナトリウム含有水性貼付剤 | |
US8153742B2 (en) | Acrylic polymer-based adhesives | |
EP2865377B1 (en) | Percutaneous absorption promoter and skin patch comprising same | |
TWI520733B (zh) | Contains lidocaine gel preparations | |
KR20030005338A (ko) | 시이트상 팩제 | |
TWI451884B (zh) | 含有鹽酸布特那芬之水性貼附劑 | |
JP6234936B2 (ja) | ロピニロール含有貼付剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |